Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II ranibizumab port delivery system study in Japanese patients with nAMD or DME
jRCT2071210073Phase 2Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Mar 2022
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ranibizumab in exudative macular degeneration and diabetic macular edema (DME) (2 cohorts), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Ocular adverse events, Non-ocular adverse events and 2 more. Started Mar 2022; status: active, not recruiting.
02
Drugs
ranibizumab
03
Conditions
exudative macular degenerationdiabetic macular edema (DME)
Beyond the preview
Go deeper on jRCT2071210073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210073.